Compare OSS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | CCCC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 185.1M |
| IPO Year | 2017 | 2020 |
| Metric | OSS | CCCC |
|---|---|---|
| Price | $8.39 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.50 | ★ $12.20 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,027,382.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.46 | 1.02 |
| 52 Week Low | $1.85 | $1.09 |
| 52 Week High | $12.75 | $3.64 |
| Indicator | OSS | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 72.10 |
| Support Level | $7.96 | $1.96 |
| Resistance Level | $10.74 | N/A |
| Average True Range (ATR) | 0.82 | 0.27 |
| MACD | -0.12 | 0.12 |
| Stochastic Oscillator | 20.18 | 92.71 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.